Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
-
J Coll Physicians Surg Pak · Aug 2021
Case ReportsRare Presentations of Rapidly Growing Liposarcomas.
Liposarcomas (LSs) are a rare form of malignant tumors. They are the most common primary neoplasms of the retroperitoneum. While these tumors rarely metastasise, they are characterised by local recurrence and infiltration. ⋯ The first case is that of a 53-year Dominican male, who developed a massive recurrence of his retroperitoneal LS within a span of just two months after initial resection ̶ an exceedingly rare occurrence. The second case is that of a 67-year Peruvian female, who was found to have a retroperitoneal LS, causing complete displacement of the viscera in her right hemiabdomen. Key Words: Liposarcomas, Recurrence, Retroperitoneum.
-
J Coll Physicians Surg Pak · Aug 2021
Case ReportsHemophagocytic Lymphohistiocytosis in a Pediatric Patient.
Hemophagocytic Lymphohistiocytosis (HLH) is an uncommon but a potentially fatal disease characterised by high grade fever, hepato-splenomegaly, deranged liver functions, cytopenias and multi-organ involvement. HLH has its own diagnostic criteria, which comprise of various clinical and laboratory features, which were revised in 2004 by HLH Society for prompt identification and recognition. Here, we present a case of 9-year developmentally normal female with all the complaints as mentioned above, who received treatment for almost eight months as a case of pyrexia of unknown origin (PUO) without a definitive diagnosis. ⋯ The diagnosis of HLH was made after fulfillment of its criteria which was addressed completely and found veracious. After addressing the active complaints of the patient, she was referred to a pediatric oncologist for chemotherapy and further management; and counselled for hematopoietic stem cell transplantation (HSCT). Key Words: Hemophagocytic lymphohistiocytosis, Pyrexia of unknown origin (PUO), Pediatric hematopoietic stem cell transplantation.
-
J Coll Physicians Surg Pak · Aug 2021
The Need for Effective Adjuvant Therapy in Uterine Leiomyosarcoma: A Single-centre Experience.
To evaluate the efficacy of adjuvant chemotherapy (ACTx) in completely resected uterine leiomyosarcoma (ULMS) in terms of survival outcomes. ⋯ Forty-five patients with a median age of 52.1 years (IQR, 45.8-58.2) were included in the study. Group I consisted of 26 (57.8%) patients and group II consisted of 19 (42.2%) patients. Median RFS was 43.8 months (95% CI, 7.4-80.2) and the median OS was 81.3 months (95% CI, 39.4-123.1) for all patients (N = 45). Median RFS was 27.1 months (95% CI, 6.8-47.4) in group I (n = 26) and 43.8 months (95% CI, 11.8-75.8) in group II (n = 19) (p = 0.985). Median OS was 85.6 months (95% CI, 38.3-132.9) in group I (n = 26) and 81.2 months (95% CI, 62.1-100.4) in group II (n = 19) (p = 0.699). Conclusion: There was no survival benefit of ACTx in completely resected ULMSs, in accordance with the literature data. There is a need for prospective randomised clinical trials evaluating the role of ACTx in ULMSs. Key Words: Uterine leiomyosarcoma, Complete resection, Adjuvant chemotherapy, Relapse, RFS, OS.